Paid Clinical Trials Bakersfield

Discover 81 paid clinical trials in Bakersfield, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 81

A Phase 1/1b Study of ZH9 Treatment in Patients with Non-Muscle Invasive Bladder CancerA Phase 1/1b Study of ZH9 Treatment in Patients with Non-Muscle Invasive Bladder Cancer

Recruiting

PHASE1

Sponsor:

Prokarium Ltd

Location:

Bakersfield CA, San Antonio TX, Durham NC, Myrtle Beach SC

Code:

NCT06181266

Conditions

NMIBC

High Risk NMIBC

Non Muscle Invasive Bladder Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

ZH9

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe DiseaseA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Recruiting

PHASE3

Sponsor:

Pfizer

Location:

Bakersfield CA, Oxnard CA, Los Angeles CA, Long Beach CAshow 42 more

Code:

NCT06679140

Conditions

COVID-19 SARS-CoV-2 Infection

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

ibuzatrelvir

placebo

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral NeuropathyEvaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Recruiting

PHASE2

Sponsor:

Vertex Pharmaceuticals Incorporated

Location:

Bakersfield CA, La Mesa CA, Meridian ID, Wheat Ridge COshow 22 more

Code:

NCT06619860

Conditions

Diabetic Peripheral Neuropathic Pain

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

VX-993

Pregabalin

Placebo (matched to pregabalin)

Placebo (matched to VX-993)

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung CancerTalazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Recruiting

PHASE2

Sponsor:

Jonsson Comprehensive Cancer Center

Location:

Bakersfield CA, Los Angeles CA, Fullerton CA, Wichita KSshow 2 more

Code:

NCT03672773

Conditions

Recurrent Extensive Stage Small Cell Lung Carcinoma

Refractory Extensive Stage Small Cell Lung Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Talazoparib

Temozolomide

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Bakersfield CA, Santa Monica CA, Los Angeles CA, Fresno CAshow 68 more

Code:

NCT03486873

Conditions

Solid Tumors

Hematologic Malignancies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Standard of Care (SOC)

Lenvatinib

Olaparib

MK-4280

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior UveitisA Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Recruiting

PHASE3

Sponsor:

Priovant Therapeutics, Inc.

Location:

Bakersfield CA, Beverly Hills CA, Los Angeles CA, Fullerton CAshow 33 more

Code:

NCT06431373

Conditions

Uveitis, Posterior

Uveitis, Intermediate

Uveitis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Brepocitinib PO QD

Placebo PO QD

A Clinical Study of V940 and BCG in People With Bladder Cancer (V940-011/INTerpath-011)A Clinical Study of V940 and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Recruiting

PHASE2

Sponsor:

Merck Sharp & Dohme LLC

Location:

Bakersfield CA, Torrance CA, Los Alamitos CA, Hialeah FL

Code:

NCT06833073

Conditions

Urinary Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Carcinoma in Situ

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

V940

BCG

A Study of Milvexian in Participants After a Recent Acute Coronary SyndromeA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

Recruiting

PHASE3

Sponsor:

Janssen Research & Development, LLC

Location:

Bakersfield CA, Northridge CA, Pasadena CA, Santa Monica CAshow 162 more

Code:

NCT05754957

Conditions

Acute Coronary Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Milvexian

Placebo

Safety and Tolerability Study of GIM-531 in Advanced Solid TumorsSafety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Recruiting

PHASE1

PHASE2

Sponsor:

Georgiamune Inc

Location:

Bakersfield CA, Los Angeles CA, Fullerton CA, San Francisco CAshow 6 more

Code:

NCT06425926

Conditions

Melanoma Stage IV

Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

GIM-531

Anti-PD-1 monoclonal antibody

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both EyesA Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Recruiting

PHASE1

Sponsor:

Amneal Pharmaceuticals, LLC

Location:

Bakersfield CA, Newport Beach CA, Houston TX, Morrow GA

Code:

NCT06267274

Conditions

Open-angle Glaucoma

Ocular Hypertension

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bimatoprost Ophthalmic Solution, 0.01%

LUMIGAN® (bimatoprost ophthalmic solution) 0.01%